Kardigan’s $1.4bn IPO plan tests investor appetite for late-stage cardiovascular biotech
Find out how Kardigan’s planned Nasdaq IPO could reshape precision cardiovascular drug development and biotech investor sentiment.
Bayer’s asundexian FDA priority review puts Factor XIa inhibition closer to a real stroke prevention test
Bayer needs a new cardiovascular growth engine. Asundexian’s FDA priority review now tests whether Factor XIa can move from promise to practice.